Frontiers in Microbiology · 2020 · 64 citations · 27 references
Life SciencesMicrobiologyMolecular BiologyAntimicrobial ResistanceMicrobial GeneticsMolecular PharmacologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance GeneticsEfflux-mediated ResistancePulmonary TuberculosisTuberculosis PharmacotherapyAntibiotic Resistance GenesAntimicrobial Resistance PatternsMolecular Drug ResistanceMolecular Drug Susceptibility TestingMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisResistance In Clinical IsolatesTuberculosis Drug Resistance
Tuberculosis (TB) is one of the major causes of deaths related to antimicrobial resistance worldwide because of the spread of Mycobacterium tuberculosis multidrug resistant (MDR and XDR) clinical isolates. To fight MDR and XDR tuberculosis, three new antitubercular drugs, bedaquiline (BDQ), delamanid, and pretomanid were approved for their use in clinical setting. Unfortunately, BDQ quickly acquired two main mechanisms of resistance, consisting in the mutations in both atpE gene, encoding the target, and in Rv0678, coding for the repressor of MmpS5-MmpL5 efflux pump. To better understand the spreading of BDQ resistance in MDR- and XDR- TB, in vitro studies could be a valuable tool. To this aim, in this work an in vitro generation of M. tuberculosis mutants resistant to BDQ was performed starting from two MDR clinical isolates as parental cultures. The two M. tuberculosis MDR clinical isolates were firstly characterized by whole genome sequencing, finding the main mutations responsible for their MDR phenotype. Furthermore, several M. tuberculosis BDQ resistant mutants were isolated by both MDR strains, harboring mutations in both atpE and Rv0678 genes. These BDQ resistant mutants were further characterized by studying their growth rate that could be related to their spreading in clinical settings. Finally, we also constructed a data sheet including the mutations linked to BDQ resistance that could be useful for the early detection of BDQ-resistance in MDR/XDR patients with the purpose of a better management of antibiotic resistance in clinical settings.
27
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Stewart T. Cole, Roland Brosch, Julian Parkhill et al. · Nature · 1998 · 7.9K citations · Full text
A Diarylquinoline Drug Active on the ATP Synthase of <i>Mycobacterium tuberculosis</i>
Koen Andries, Peter Verhasselt, Jérôme Guillemont et al. · Science · 2004 · 2.2K citations · Full text
Juan-Carlos Palomino, Anandi Martin, Mirtha Camacho et al. · Antimicrobial Agents and Chemotherapy · 2002 · 1.2K citations · Full text